ZYNERBA PHARMACEUTICALS INC's ticker is ZYNE and the CUSIP is 98986X109. A total of 44 filers reported holding ZYNERBA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $20,000 | -82.9% | 16,650 | -52.8% | 0.00% | -100.0% |
| Q3 2020 | $117,000 | -17.0% | 35,293 | -16.2% | 0.00% | 0.0% |
| Q2 2020 | $141,000 | -11.3% | 42,093 | +1.2% | 0.00% | 0.0% |
| Q1 2020 | $159,000 | -40.0% | 41,593 | -5.1% | 0.00% | -50.0% |
| Q4 2019 | $265,000 | -20.4% | 43,843 | -0.1% | 0.00% | 0.0% |
| Q3 2019 | $333,000 | -61.6% | 43,868 | -31.4% | 0.00% | -60.0% |
| Q2 2019 | $867,000 | +67.4% | 63,993 | -33.0% | 0.01% | +66.7% |
| Q1 2019 | $518,000 | +106.4% | 95,493 | +13.0% | 0.00% | +50.0% |
| Q4 2018 | $251,000 | -66.4% | 84,493 | -7.9% | 0.00% | -60.0% |
| Q3 2018 | $748,000 | -7.9% | 91,743 | +10.0% | 0.01% | -16.7% |
| Q2 2018 | $812,000 | +12.0% | 83,393 | 0.0% | 0.01% | 0.0% |
| Q1 2018 | $725,000 | -30.7% | 83,393 | 0.0% | 0.01% | -33.3% |
| Q4 2017 | $1,046,000 | – | 83,393 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 507,191 | $5,107,000 | 0.50% |
| Cormorant Asset Management, LP | 356,600 | $3,591,000 | 0.43% |
| Perceptive Advisors | 558,446 | $5,623,000 | 0.42% |
| NEXTHERA CAPITAL LP | 15,000 | $151,000 | 0.21% |
| EMERALD ADVISERS, LLC | 237,070 | $2,387,000 | 0.11% |
| AUXIER ASSET MANAGEMENT | 17,857 | $180,000 | 0.04% |
| FEDERATED HERMES, INC. | 450,000 | $4,532,000 | 0.01% |
| Nationwide Fund Advisors | 49,473 | $498,000 | 0.00% |
| Catalyst Capital Advisors LLC | 348 | $4,000 | 0.00% |
| DEUTSCHE BANK AG\ | 859 | $8,000 | 0.00% |